Systematic Review of P-magnetic Resonance Spectroscopy Studies of Brain High Energy Phosphates and Membrane Phospholipids in Aging and Alzheimer's Disease

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2023 Jun 5

PMID 37273652

Authors

Steven Jett

Camila Boneu

Camila Zarate

Caroline Carlton

Vibha Kodancha

Matilde Nerattini

Michael Battista

Silky Pahlajani

Schantel Williams

Jonathan P Dyke

Lisa Mosconi

Affiliations

Soon will be listed here.

Abstract

Many lines of evidence suggest that mitochondria have a central role in aging-related neurodegenerative diseases, such as Alzheimer's disease (AD). Mitochondrial dysfunction, cerebral energy dysmetabolism and oxidative damage increase with age, and are early event in AD pathophysiology and may precede amyloid beta (Aβ) plaques. probes of mitochondrial function and energy metabolism are therefore crucial to characterize the bioenergetic abnormalities underlying AD risk, and their relationship to pathophysiology and cognition. A majority of the research conducted in humans have used F-fluoro-deoxygluose (FDG) PET to image cerebral glucose metabolism (CMRglc), but key information regarding oxidative phosphorylation (OXPHOS), the process which generates 90% of the energy for the brain, cannot be assessed with this method. Thus, there is a crucial need for imaging tools to measure mitochondrial processes and OXPHOS in the human brain. Phosphorus-magnetic resonance spectroscopy (P-MRS) is a non-invasive method which allows for the measurement of OXPHOS-related high-energy phosphates (HEP), including phosphocreatine (PCr), adenosine triphosphate (ATP), and inorganic phosphate (Pi), in addition to potential of hydrogen (pH), as well as components of phospholipid metabolism, such as phosphomonoesters (PMEs) and phosphodiesters (PDEs). Herein, we provide a systematic review of the existing literature utilizing the P-MRS methodology during the normal aging process and in patients with mild cognitive impairment (MCI) and AD, with an additional focus on individuals at risk for AD. We discuss the strengths and limitations of the technique, in addition to considering future directions toward validating the use of P-MRS measures as biomarkers for the early detection of AD.

Citing Articles

Therapeutic assessment of a novel mitochondrial complex I inhibitor in and models of Alzheimer's disease.

Trushin S, Nguyen T, Stojacovic A, Ostroot M, Trey Deason J, Chang S bioRxiv. 2025; .

PMID: 40027647 PMC: 11870434. DOI: 10.1101/2025.02.12.637918.

Feasibility and comparison of 3D modified rosette ultra-short echo time (PETALUTE) with conventional weighted acquisition in P-MRSI.

Bozymski B, Shen X, Ozen A, Chiew M, Thomas M, Clarke W Sci Rep. 2025; 15(1):6465.

PMID: 39987281 PMC: 11846993. DOI: 10.1038/s41598-025-90630-y.

Targeting mitophagy in neurodegenerative diseases.

Antico O, Thompson P, Hertz N, Muqit M, Parton L Nat Rev Drug Discov. 2025; .

PMID: 39809929 DOI: 10.1038/s41573-024-01105-0.

Variable bioenergetic sensitivity of neurons and astrocytes to insulin and extracellular glucose.

Sims S, Frazier H, Case S, Lin R, Trosper J, Vekaria H NPJ Metab Health Dis. 2024; 2(1):33.

PMID: 39524535 PMC: 11549053. DOI: 10.1038/s44324-024-00037-y.

Neurocognitive correlates of cerebral mitochondrial function and energy metabolism using phosphorus magnetic resonance spectroscopy in older adults.

Lopez F, OShea A, Huo Z, DeKosky S, Trouard T, Alexander G Geroscience. 2024; .

PMID: 39477865 DOI: 10.1007/s11357-024-01403-w.

References

Gibson G, Huang H . Oxidative stress in Alzheimer's disease. Neurobiol Aging. 2005; 26(5):575-8. DOI: 10.1016/j.neurobiolaging.2004.07.017. View

Raichle M . Two views of brain function. Trends Cogn Sci. 2010; 14(4):180-90. DOI: 10.1016/j.tics.2010.01.008. View

Ferretti M, Iulita M, Cavedo E, Chiesa P, Dimech A, Chadha A . Sex differences in Alzheimer disease - the gateway to precision medicine. Nat Rev Neurol. 2018; 14(8):457-469. DOI: 10.1038/s41582-018-0032-9. View

Lawson B, Anday E, Guillet R, Wagerle L, Chance B, Delivoria-Papadopoulos M . Brain oxidative phosphorylation following alteration in head position in preterm and term neonates. Pediatr Res. 1987; 22(3):302-5. DOI: 10.1203/00006450-198709000-00013. View

Longo R, Ricci C, Dalla Palma L, Vidimari R, Giorgini A, den Hollander J . Quantitative 31P MRS of the normal adult human brain. Assessment of interindividual differences and ageing effects. NMR Biomed. 1993; 6(1):53-7. DOI: 10.1002/nbm.1940060109. View

Alle H, Roth A, Geiger J . Energy-efficient action potentials in hippocampal mossy fibers. Science. 2009; 325(5946):1405-8. DOI: 10.1126/science.1174331. View

Anandatheerthavarada H, Biswas G, Robin M, Avadhani N . Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol. 2003; 161(1):41-54. PMC: 2172865. DOI: 10.1083/jcb.200207030. View

Parasoglou P, Osorio R, Khegai O, Kovbasyuk Z, Miller M, Ho A . Phosphorus metabolism in the brain of cognitively normal midlife individuals at risk for Alzheimer's disease. Neuroimage Rep. 2022; 2(4. PMC: 9757821. DOI: 10.1016/j.ynirp.2022.100121. View

Forbes S, Cordingley D, Cornish S, Gualano B, Roschel H, Ostojic S . Effects of Creatine Supplementation on Brain Function and Health. Nutrients. 2022; 14(5). PMC: 8912287. DOI: 10.3390/nu14050921. View

10.

Hangel G, Niess E, Lazen P, Bednarik P, Bogner W, Strasser B . Emerging methods and applications of ultra-high field MR spectroscopic imaging in the human brain. Anal Biochem. 2021; 638:114479. DOI: 10.1016/j.ab.2021.114479. View

11.

Beard E, Braissant O . Synthesis and transport of creatine in the CNS: importance for cerebral functions. J Neurochem. 2010; 115(2):297-313. DOI: 10.1111/j.1471-4159.2010.06935.x. View

12.

Yao J, Irwin R, Chen S, Hamilton R, Cadenas E, Brinton R . Ovarian hormone loss induces bioenergetic deficits and mitochondrial β-amyloid. Neurobiol Aging. 2011; 33(8):1507-21. PMC: 3181273. DOI: 10.1016/j.neurobiolaging.2011.03.001. View

13.

Mandal P, Akolkar H, Tripathi M . Mapping of hippocampal pH and neurochemicals from in vivo multi-voxel 31P study in healthy normal young male/female, mild cognitive impairment, and Alzheimer's disease. J Alzheimers Dis. 2012; 31 Suppl 3:S75-86. DOI: 10.3233/JAD-2012-120166. View

14.

Ross B, Moszczynska A, Erlich J, Kish S . Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity. J Neurochem. 1998; 70(2):786-93. DOI: 10.1046/j.1471-4159.1998.70020786.x. View

15.

Silveri M, Dikan J, Ross A, Jensen J, Kamiya T, Kawada Y . Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. 2008; 21(10):1066-75. DOI: 10.1002/nbm.1281. View

16.

Farrer L, Cupples L, Haines J, Hyman B, Kukull W, Mayeux R . Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997; 278(16):1349-56. View

17.

Hampel H, Cummings J, Blennow K, Gao P, Jack Jr C, Vergallo A . Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol. 2021; 17(9):580-589. DOI: 10.1038/s41582-021-00520-w. View

18.

Chen C, Stephenson M, Peters A, Morris P, Francis S, Gowland P . P magnetization transfer magnetic resonance spectroscopy: Assessing the activation induced change in cerebral ATP metabolic rates at 3 T. Magn Reson Med. 2017; 79(1):22-30. PMC: 5706641. DOI: 10.1002/mrm.26663. View

19.

Xiang X, Wind K, Wiedemann T, Blume T, Shi Y, Briel N . Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases. Sci Transl Med. 2021; 13(615):eabe5640. DOI: 10.1126/scitranslmed.abe5640. View

20.

Petersen R . Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183-94. DOI: 10.1111/j.1365-2796.2004.01388.x. View